Country websites:


The medical device and therapy related information on this website is aimed exclusively at healthcare professionals located within the European Union.

Not all products are cleared or available for sale in all EU countries. Please check the relevant country web site for details.

By clicking on the button “Accepted and Confirmed” you assure that you have taken note of this information and that you are a healthcare professional located within the European Union.

FX Dialyzers

FX Coral Hero Teaser

Belong together
Clinical Performance +



Not all products and services are cleared or available for sale in all EU countries. Check your country web site for details. 

Why FX properties make a difference

FX portfolio

Nurse - treatment quote for FX Dialyzers

"A smooth treatment is the difference that allows us to focus more on the patient."

  • 1. Lateral blood inlet port
  • 2. System compatibility and more
  • 3. Sophisticated fiber architecture
  • 4. Optimized header design
  • 5. INLINE steam sterilization
  • 6. Sustainable product design

Smooth handling

Simplified workflows

Improved clearances

Enhanced performance

Setting the standard

Adding value across the entire life cycle

Eco-performance radar
Patient - treatment quote for FX Dialyzers

"The difference is feeling confident throughout the entire treatment."

The blue art project

We asked artists to interpret the benefits of the FX Dialyzers in their own way. The color blue of the FX Dialyzer caps became their inspiration point.

Find out more
Hospital Head - treatment quote for FX Dialyzers

"Reliability and experience make a difference when seeking the best solutions."

* FX CorAL is a registered trademark of Fresenius Medical Care in selected countries.
1 Wagner S. et al., Nephrology Dialysis Transplantation (2017); 32 (3): iii615.
2 Bock A. et al., J Am Soc Nephrol (2013); 24: SA-PO404.
3 Maduell F. et al., Blood Purif. (2014); 37(2): 125-130.
4 Lim P. S. et al., Artif Organs (2017); Nov 27. doi: 10.1111/aor.13011.
5 Schindler R. et al., Clin. Nephrology (2003); 59: 447–454.
6 Weber V. et al., Artif Organs (2004); 28(2): 210-217.
7 Chazot C. et al., Nephron (2015); 129: 269-275.
8 Tsai I.J. et al., Pediatr Nephrol (2014); 29: 111–116.
9 Data from Fresenius Medical Care Deutschland GmbH: Comparison clearance values F8 HPS (effective surface area 1.8 m2) versus FX 8 (effective surface area 1.4 m2).
10 Ronco C., Nissenson A. R., Blood Purif (2001); 19: 347-352.
11 Ronco C. et al., Kidney International (2002); 61 (80): 126-142.
12 Külz M. et al., Nephrol Dial Transplant (2002); 17: 1475-1479.
13 Mandolfo S. et al., The International Journal of Artificial Organs (2003); 26 (2): 113-120.
14 Allard B. et al., Le Pharmacien Hospitalier et Clinicien (2013); 48 (4): 15-21.
15 Shintani H., Biomedical instrumentation & technology (1995); 29 (6): 513–519.
16 Hirata N. et al., Radiation Physics and Chemistry (1995); 46 (3): 377–381.
17 Golli-Bennour E. E. et al., International urology and nephrology (2011); 43 (2): 483–490.
18 Azzabi A. et al., Néphrologie & Thérapeutique (2014); 10 (5): 318.
19 Golli-Bennour E.E et al., World J Nephrol Urol (2017); 6 (1-2): 14-17.
20 da Silva Aquino K. A., INtechOpen (2012); (27.04.2018).
21 Dawids S., Handlos V. N., Developments in hematology and immunology (1989); 347–368.
22 Unpublished data from Fresenius Medical Care Deutschland GmbH: Internal calculation based on weight measurements before treatment of FX Dialysers versus F-series dialysers.
23 Unpublished data from Fresenius Medical Care Deutschland GmbH: Internal calculation based on weight measurements of FME FX classix 80 versus FME HF 80S. The typical number of treatments in most clinics is approximately 10,000 per year; this results in about 1,600 kg less waste being produced annually with FX classix 80 when used on FME 5008 CorDiax machine.
24 EC-JRC-IES (2011): ILCD handbook – Recommendations for LCIA in the European context. Source: (all 15 environmental impact categories with recommendation in table 1 of this ILCD handbook have been evaluated).
25 Unpublished data from Fresenius Medical Care Deutschland GmbH internal study (2018): Comparative life cycle assessment of selected FME dialysers. Eco-performance is always calculated versus baseline product (FME HF 80S); long distance scenario illustrated.
26 Melchior P et al., Complement activation by dialysis membranes and its association with secondary membrane formation and surface charge. Artif Org 2020, Dec 16, doi:10.1111/aor.13887.
27 Zawada A et al., PVP in hemodialysis membranes: impact on platelet loss during hemodialysis – manuscript submitted.
28 Ehlerding et al., Performance and hemocompatibility of a novel polysulfone dialyzer: a randomized controlled trial. Kidney360 2021, April 7, doi:10.34067/KID.0000302021.
29 Unpublished internal data on file – comPERFORM study